SBIR/STTR Research Award

CYCLIC AMP BINDING PROTEINS AND RAS FUNCTION

Award identifier 31c3da506826f9761ef6f0a19315e636d3773b9805fda60e935b5144e3fa72c8Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1992

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Sphinx Pharmaceuticals
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

TWO CAMP BINDING PROTEINS (50K AND 10K DALTONS) THAT ALTER BIOCHEMICAL PROPERTIES OF PROTOON- COGENE RAS IN A CAMP DEPENDENT MANNER WERE ISOLATED FROM BOVINE BRAIN. IN THE PRESENCE OF CAMP, THE 50K DALTON PROTEIN (P50) INHIBITED THE NUCLEOTIDE EXCHANGE OF RAS, WHEREAS THE 10K PROTEIN (P10) INHIBITED NUCLEOTIDE BINDING. IN THE ABSENCE OF CAMP, THESE TWO PROTEINS ARE TOTALLY INACTIVE. IT IS WELL ESTABLISHED THAT PROTOONCOGENE RAS PLAYS AN IMPORTANT ROLE IN CONTROLLING CELL PROLIFERATION AND DIFFERENTIATION. THE INTERACTION BETWEEN THESE TWO PROTEINSAND RAS MAY REPRESENT A NOVEL MECHANISM BY WHICH CELL PROLIFERATION AND DIFFERENTIATION. THE INTERACTION BETWEEN THESE TWO PROTEINS AND RAS MAY REPRESENT A NOVEL MECHANISM BY WHICH CELL PROLIFERATION AND DIFFERENTIATION ARE REGULATED. THE OBJECTIVE OF THIS PHASE I PROJECT IS TO PARTIALLY PURIFY THESE TWO PROTEINS, ESTABLISHED A STANDARD ASSAY AND SCREEN FOR THE COMPOUND OR NATURAL PRODUCTS THAT ARE ABLE TO ALTER THE BIOCHEMICAL AND BIOLOGICAL ACTIVITY OF THESE TWO PROTEINS. THE COMPOUNDS IDENTIFIED IN THIS PHASE I STUDY MAY DEVELOP INTO POTENTIAL ANTI- PROLIFERATIVE DRUGS. IN THE PHASE II PORTION OF THIS GRANT, THESE TWO PROTEINS WILL BE PURIFIED, SEQUENCED AND CLONED. THE BIOLOGICAL SIGNIFICANCE OF THESE TWO PROTEINS WILL BE ELUCIDATED BY INTRODUCTING THESE TWO PROTEINS INTO CULTURED CELLS BY PROTEIN MICROINJECTION AND/OR GENE TRANSFER TECHNIQUES. ALTERNATIVELY, ANTIBODIES THAT ARE ABLE TO NEUTRALIZE THESE TWO PROTEINS WILL BE MICROINJECTED INTO CULTURED CELLS TO DETERMINE THE BIOLOGICAL FUNCTION OF THESE TWO PROTEINS. THE CELL MODEL WILL BE ESTABLISHED TO SCREEN THE COMPOUNDS THAT ARE ABLE TO ALTER THE BIOLOGICAL ACTIVITY OF THESE TWO PROTEINS.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.